blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3946547

EP3946547 - DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  07.01.2022
Database last updated on 29.06.2024
FormerThe international publication has been made
Status updated on  03.10.2020
Most recent event   Tooltip03.01.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Pocket Naloxone Corp.
9101 Quintana Drive
Bethesda, Maryland 20817 / US
[2022/06]
Inventor(s)01 / MATHAI, Ashanthi
9101 Quintana Drive
Bethesda, Maryland 20817 / US
[N/P]
Former [2022/06]01 / MATHAI, Ashanthi
Bethesda, Maryland 20817 / US
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[N/P]
Former [2022/06]Nieuwenhuys, William Francis
Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
Application number, filing date20778140.225.03.2020
[2022/06]
WO2020US24661
Priority number, dateUS201962823800P26.03.2019         Original published format: US 201962823800 P
US202062981929P26.02.2020         Original published format: US 202062981929 P
[2022/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020198327
Date:01.10.2020
Language:EN
[2020/40]
Type: A1 Application with search report 
No.:EP3946547
Date:09.02.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 01.10.2020 takes the place of the publication of the European patent application.
[2022/06]
Search report(s)International search report - published on:US01.10.2020
(Supplementary) European search report - dispatched on:EP21.12.2022
ClassificationIPC:A61M35/00, A61M37/00, A61M5/00, A61B17/24, A61K31/485, A61K9/00, A61K45/06, A61M29/02, A61M31/00, A61F13/40
[2023/03]
CPC:
A61K31/485 (EP,US); A61M31/00 (EP,US); A61K45/06 (EP);
A61K9/0043 (EP,US); A61K9/08 (US); A61M29/02 (EP);
A61M2205/3368 (US); A61M2210/0618 (EP,US); A61M35/006 (EP) (-)
Former IPC [2022/06]A61M35/00, A61M37/00, A61M5/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/06]
TitleGerman:VORRICHTUNGEN UND VERFAHREN ZUR ABGABE VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN[2022/06]
English:DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS[2022/06]
French:DISPOSITIFS ET PROCÉDÉS D'ADMINISTRATION DE COMPOSITIONS PHARMACEUTIQUES[2022/06]
Entry into regional phase26.10.2021National basic fee paid 
26.10.2021Search fee paid 
26.10.2021Designation fee(s) paid 
26.10.2021Examination fee paid 
Examination procedure26.10.2021Examination requested  [2022/06]
21.07.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
28.03.2022Renewal fee patent year 03
14.02.2023Renewal fee patent year 04
03.01.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2012156317  (EURO CELTIQUE SA [LU], et al) [A] 1-9 * claim 1 *;
 [Y]US2015265752  (WEI EDWARD T [US]) [Y] 1-9 * abstract * * claim 1 * * figures 1-2 *;
 [Y]US2015297617  (GIVEN JOHN T [US], et al) [Y] 1-9 * abstract * * paragraphs [0043] , [0084] *;
 [A]US2016184564  (SPEARMAN MICHAEL R [US], et al) [A] 1-9 * abstract * * claim 1 * * figure 1 *;
 [A]WO2016132223  (TAMIR IDAN [IL]) [A] 1-9 * claim - ** figures 2,3,4A *
International search[A]US5562077  (SCHULTZ JOSEPH [US]) [A] 148-156, 157/153-156, 158* ; Figure 1; Column 4, Lines 62-67 *;
 [Y]WO0062757  (BRITANNIA PHARMACEUTICALS LTD [GB], et al) [Y] 1-46, 47/29-46, 48/29-46, 49/29-37, 49/39-46, 50-55, 59-78, 80-89, 90/72-89, 91/72-75, 91/76-82, 91/84-89, 92/72-80, 92/82-89, 93-96, 100, 101, 121 * ; Abstract; Page 1, Second Paragraph; Page 2, Seventh Paragraph; Page 1, Second Paragraph; Page 4, Sixth Paragraph; Page 5, Fifth Paragraph to Page 6, First Paragraph; Claim 2; Figures 1(a), 2 *;
 [Y]WO2007126851  (INTELLIJECT LLC [US], et al) [Y] 5, 63 * ; Abstract; Paragraphs [1013], [1339], [1361], [1433] *;
 [Y]US2011256070  (MARTIN JAMES H [US], et al) [Y] 38, 47/38, 48/38, 81, 90/81, 91/81 * ; Abstract; Paragraphs [0013], [0031]; Claim 12 *;
 [XYA]US2013085472  (SHAARI CHRISTOPHER [US]) [X] 100, 102-110, 115-120, 122-129, 133-135, 137-141, 142/137-141 * ; Abstract; Figures 1A, 1C, 1D, 1 E1, 2A1, 3A2, 3B, 3C; Paragraphs [0008], [0022], [0027], [0029], [0034]-[0037], [0043], [0046], [0047], [0059]; Claims 3, 7, 15, 16, 27, 86 * [Y] 1-46, 47/29-46, 48/30-46, 49/29-37, 49/39-46, 50-54, 59-75, 76-89, 90/72-75, 90/76-81, 90/83-89, 91/72, 91/73-89, 92/72-80, 92/82-89, 93-96, 100, 101, 111-114, 121, 130-132, 143-146, 147/143-146 [A] 148-156, 157/153-156, 158;
 [Y]US2015283091  (VARGAS RINCON RICARDO ALBERTO [CA]) [Y] 36, 40, 47/36, 47/40, 48/36, 48/40, 49/36, 49/40, 52, 53, 79, 83, 90/79, 90/83, 91/79, 91/83, 92/79, 92/83 * ; Abstract; Paragraphs [0079], [0177], [0196], [0227]; Claims 14, 30 *;
 [Y]US2016038406  (HARIHARAN MADHU [US]) [Y] 39, 47/39, 48/39, 49/39, 82, 90/82, 91/82, 92/82 * ; Abstract; Paragraphs [0002], [0003], [0020], [0074]; Claim 3 *;
 [Y]US2016158464  (HIJLKEMA MARKUS [GB], et al) [Y] 20, 114, 132, 145, 147/145 * : Abstract: Paragraph [0020] *;
 [A]US2016339198  (FRASER JOHN FRANCIS [AU], et al) [A] 148-156, 157/153-156, 158 * ; Abstract; Paragraphs [0130], [0154] *;
 [Y]US2017165255  (YUM SU IL [US], et al) [Y] 30-32, 37, 41, 47/30-32, 47/37, 47/41, 48/30-32, 48/37, 48/41, 49/30-32, 49/37, 49/41, 73-75, 80, 84, 90/73-75, 90/80, 90/84, 91/73-75, 91/80, 91/84, 92/73-75, 92/80, 92/84 * ; Abstract; Paragraphs [0027], [0039], [0040], [0044], [0051], [0129]; Claim 80 *;
 [Y]US2017304192  (STRANG JOHN [GB], et al) [Y] 54, 55, 95, 96 * ; Abstract; Paragraphs [0246]-[0248]; Claim 22 *;
 [Y]US2018030405  (SUBHADRA BOBBAN [US]) [Y] 17-20, 111-114, 130-132, 143-146, 147/143, 147/144-146 * ; Abstract; Figure 7; Paragraph [0034] *;
 [Y]US2018133731  (RITSCHE STEFAN [DE]) [Y] 3, 61 * ; Abstract; Figures 2A, 2B; Paragraphs [0018], [0030], [0053]; Claims 1, 3 *;
 [A]US2019070396  (JOHNSON RANDOLPH M [US], et al) [A] 148-156, 157/153-156, 158 * ; Figures 1A, 2; Paragraphs [0010], [0011]; Claims 1, 7 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.